BioCentury | Apr 29, 2013
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

...that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte...
BioCentury | Feb 27, 2012
Clinical News

Ion paclitaxel-eluting coronary stent regulatory update

...FDA approved the Ion and Taxus Liberte paclitaxel-eluting coronary stent systems from Boston Scientific to treat acute...
...to treat acute myocardial infarction. Both are next-generation drug-eluting coronary platinum chromium alloy stent systems. Taxus Liberte...
...July 14, 1997). Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Ion paclitaxel-eluting coronary stent , Taxus Liberte...
BioCentury | Oct 11, 2010
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Completed Phase II enrollment

...in the open-label, international Phase II REMEDEE trial to compare its Combo Bio-engineered stent vs. Taxus Liberte...
BioCentury | Oct 4, 2010
Clinical News

Taxus Liberte: Additional data

...Additional data from the ATLAS trial in 871 patients showed that Taxus Liberte and Taxus Express led...
...1997). Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI), Vancouver, B.C. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Taxus Liberte...
BioCentury | Oct 4, 2010
Clinical News

Taxus Liberte: Additional data

...Additional data from the ATLAS Long Lesion study showed that the Taxus Liberte Long Stent significantly reduced...
...were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington. Boston Scientific previously reported that Taxus Liberte...
...1997). Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI), Vancouver, B.C. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Taxus Liberte...
BioCentury | Oct 4, 2010
Clinical News

Taxus Liberte: Additional data

...Additional data from the ATLAS Small Vessel study showed that Taxus Liberte significantly reduced the rates of...
...of target lesion revascularization (TLR) at 4 years vs. Taxus Express (10.8% vs. 23.8%, p=0.008). Taxus Liberte...
...were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington. Boston Scientific previously reported that Taxus Liberte...
BioCentury | Jun 7, 2010
Clinical News

Xience V: Post-marketing study data

...international SPIRIT V Diabetes trial in 324 patients with diabetes, Xience V was superior to Taxus Liberte...
...the EuroPCR meeting in Paris. Abbott markets Xience V in the U.S., EU and Japan. Taxus Liberte...
BioCentury | Jun 7, 2010
Clinical News

Nevo sirolimus-eluting coronary stent: Additional pivotal trial data

...were no episodes of stent thrombosis in the Nevo arm vs. 2 events in the Taxus Liberte...
...previously reported that the trial met the primary endpoint of in-stent late lumen loss vs. Taxus Liberte...
...Nevo were angina-free at 6 months (see BioCentury, May 25, 2009, & Oct. 5, 2009). Taxus Liberte...
BioCentury | Mar 22, 2010
Clinical News

Taxus Express paclitaxel-eluting stent system: Additional Phase III data

...it submitted an application to FDA to expand the indication of its Taxus Express and Taxus Liberte...
BioCentury | Feb 8, 2010
Company News

Boston Scientific, J&J cardiovascular news

...patents. A third dispute, which was scheduled for a trial in September, alleged Boston Scientific's Taxus Liberte...
Items per page:
1 - 10 of 47